BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?
First Live Meeting Since 2019 Begins In San Diego
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.
